Last edition
News about "Olivier Charmeil"
EU Grants Conditional Approval to Rezurock for Chronic GVHD Treatment
European Commission authorises belumosudil for patients aged 12 plus with limited treatment options, marking a significant advance in managing a life-threatening post-transplant condition.
Olivier Charmeil | 01/04/2026 | By News Bureau
EU recommends Rezurock for CHMP approval to treat chronic GVHD
The CHMP’s positive opinion, backed by clinical trial data and real-world evidence, paves the way for Rezurock’s potential approval in the EU as a new treatment option for adult and paediatric patients aged 12 years and above with late-line chronic graft-vs-host disease.
Olivier Charmeil | 02/02/2026 | By News Bureau | 107
China's NMPA Approves Sanofi-Licensed Myqorzo and Redemplo for Rare Cardiac and Lipid Disorders
Myqorzo and Redemplo approvals by NMPA expand treatment options for obstructive hypertrophic cardiomyopathy and familial chylomicronaemia syndrome in adult patients across Greater China.
Olivier Charmeil | 17/01/2026 | By News Bureau | 266
European Commission Approves Teizeild to Delay Onset of Type 1 Diabetes
Teizeild (teplizumab) becomes the first disease-modifying therapy approved in the EU to delay progression to stage III type 1 diabetes in eligible adults and children aged eight and above.
Olivier Charmeil | 13/01/2026 | By News Bureau | 214
CHMP Recommends Sanofi's Tezeild for EU Approval in Stage 2 Type 1 Diabetes
The CHMP has backed EU approval for Sanofi’s Tezeild, supported by TN-10 study results showing the therapy can delay progression to stage 3 type 1 diabetes in patients with stage 2 disease. If authorised, Tezeild would become the first disease-modifying treatment for T1D in the EU.
Olivier Charmeil | 15/11/2025 | By Dineshwori | 333
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy